Event Details

Join us on July 14 for Bioinsight’s Cell & Gene Therapy live webinar dedicated to bringing you the latest cutting-edge research and commentary in bioscience!

E-meet Ali Mohamed for his presentation and engage in the following discussion about Immatics’ ACTolog® concept and data from the IMA101-101 trial:

Tuesday, July 14, 8am PDT (11am EDT/ 4pm BST/ 5pm CEST)

Presentation: Manufacturing of endogenous, non-engineered, antigen specific T cells against tumor targets

•Which manufacturing steps are critical in achieving a successful manufacturing of autologous antigen specific T cells?

•What are the differences between endogenous antigen-specific T cell products and engineered T cells (e.g. classical CAR or TCR-T cells)?

•How can multiparametric and closed system cell sorting be utilized in clinical application?

•How do standardization tools help achieve reproducible QC/IPC of cellular products?

And afterwards don’t miss to discuss:

•The ACTolog® concept – Immatics’ ultra-personalized, multi-target immunotherapy pilot program; including the priming, isolation, sorting, and expansion of target-specific T cells

•The exemplary manufacturing and clinical data from the IMA101-101 trial utilizing ACTolog®

•The insights into the effective application of the MACSQuant® Tyto® Cell Sorter for T cell sorting

•The utility of novel tools for the facilitation of reproducible flow cytometry-based IPC/QC processes

We are looking forward to e-meeting you!

Learn more about the Cell & Gene Therapy Insights here.